Is Vaxart a Buy?

Is Vaxart a Buy?

In the early days of the pandemic, Vaxart (NASDAQ: VXRT) mesmerized investors after beginning development of a tablet-based, room-temperature-stable coronavirus vaccine. On Feb. 3, Vaxart announced that its oral coronavirus-vaccine candidate, VXA-CoV2-1, did not induce neutralizing antibodies after a one-dose regimen. The discrepancy here puzzled many investors since the two should be in tandem with one another, as with of the coronavirus vaccines currently on the market.